drugset / Trial / NCT00845819

Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies

NCT00845819

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine efficacy and toxicity of recombinant human epidermal growth factor (rhEGF) as a preventive drug of oral mucositis during intensive chemotherapy with stem cell transplantation in patients with hematologic malignancies.

Timeline

Start
2009-02
Primary completion
2014-10
Completion
2014-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator NEPIDERMIN Protein / enzyme biologic 50 ug/ml
Comparator Chlorhexidine Small molecule 0.5 % Oral
Comparator Nystatin Unknown 5000 iu Oral
Comparator Povidone-Iodine Other / unclassified 1 % Oral